Results 101 to 110 of about 1,389,538 (204)

Adverse event reports of seizure for insomnia medication from 1967 to 2023

open access: yesScientific Reports
Insomnia may negatively impact seizure control; however, the corresponding evidence remains limited. This study analyzed the seizure risk associated with various insomnia medications using a comprehensive pharmacovigilance database and identified safe ...
Tae Hyeon Kim   +13 more
doaj   +1 more source

Dual Orexin Receptor Antagonists (DORAs) in the Management of Climacteric Insomnia: A Scoping Review

open access: yes
This scoping review aims to map the available scientific evidence regarding the efficacy, safety, and tolerability of Dual Orexin Receptor Antagonists (DORAs)—specifically suvorexant, lemborexant, and daridorexant—in treating insomnia among women during ...
Ester Saraiva Carvalho Feitosa
core  

Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis. [PDF]

open access: yesFront Pharmacol, 2023
Xue T   +7 more
europepmc   +1 more source

Sleep, wake, and signaling : functional profiling of orexin agonists and antagonists using newly developed orexin (3-arrestin 2 and miniGaq recruitment assays

open access: yes
The excitatory neuropeptides orexin-A and-B interact with their target G protein-coupled receptors (GPCRs), the orexin 1 and orexin 2 (OX1 and OX2) receptors, which are widely expressed throughout the central nervous system.
Decker, Michael   +4 more
core   +1 more source

Comparative Efficacy and Safety of Dual Orexin Receptor Antagonists-Daridorexant, Lemborexant, and Suvorexant for Insomnia: A Systematic Review and Network Meta-analysis

open access: yes
Although three dual orexin receptor antagonists (DORAs, daridorexant, lemborexant, and suvorexant) have been launched for adults with insomnia, because it is unclear which DORAs had favorable risk-benefit balance for the people, we will conduct the ...
Taro Kishi
core   +1 more source

Home - About - Disclaimer - Privacy